Well being and Human Companies Secretary Robert F. Kennedy Jr. has railed towards what he sees as a “revolving door” between employees at drug firms and the Meals and Drug Administration. However his division’s actions now appear to be inflicting that door to spin ever sooner.
Scores of FDA workers are trying to find an exit from an company in turmoil, significantly workers members tasked with reviewing drug functions, based on interviews with former workers and business recruiters. Lots of these becoming a member of the exodus had been protected against the layoffs that hit the company earlier this month, however their work surroundings has turn into morose, and cuts to different departments are making it tougher to do their jobs.
As many as 600 drug reviewers have recused themselves from approval processes as a result of they’re interviewing with pharma firms, former FDA commissioner Scott Gottlieb estimated throughout an look on CNBC’s “Squawk Field” earlier this week. These workers members oversee functions for brand spanking new medicines and are partially funded by way of consumer charges that the FDA collects from drug firms.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
